Lefamulin Tablets and Sporanox (Itraconazole Capsules (Sporanox))
Determining the interaction of Lefamulin Tablets and Sporanox (Itraconazole Capsules (Sporanox)) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 and/or P-gp may significantly increase the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral ketoconazole, a potent CYP450 3A4/P-gp inhibitor, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 58% and 165%, respectively. Coadministration of intravenous lefamulin with oral ketoconazole increased mean lefamulin Cmax and AUC by 6% and 31%, respectively. Increased exposure to lefamulin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death. MANAGEMENT: Concomitant use of lefamulin with potent inhibitors of CYP450 3A4 and/or P-gp should generally be avoided. References "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Professional:GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 and/or P-gp may significantly increase the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral ketoconazole, a potent CYP450 3A4/P-gp inhibitor, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 58% and 165%, respectively. Coadministration of intravenous lefamulin with oral ketoconazole increased mean lefamulin Cmax and AUC by 6% and 31%, respectively. Increased exposure to lefamulin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.
MANAGEMENT: Concomitant use of lefamulin with potent inhibitors of CYP450 3A4 and/or P-gp should generally be avoided.
- "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Generic Name: lefamulin
Brand name: Xenleta
Synonyms: Lefamulin Injection, Lefamulin, Lefamulin (oral/injection)
Generic Name: itraconazole
Brand name: Onmel, Sporanox, Sporanox PulsePak, Tolsura
Synonyms: Itraconazole
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Lefamulin Tablets-Sporanox (Itraconazole Oral Solution)
- Lefamulin Tablets-Sporanox Capsules
- Lefamulin Tablets-Sporanox injection
- Lefamulin Tablets-Sporanox PulsePak
- Lefamulin Tablets-Sportsmed Topical
- Lefamulin Tablets-Spravato
- Sporanox (Itraconazole Capsules (Sporanox))-Leflunomide
- Sporanox (Itraconazole Capsules (Sporanox))-Legatrin PM
- Sporanox (Itraconazole Capsules (Sporanox))-Lemtrada
- Sporanox (Itraconazole Capsules (Sporanox))-Lenalidomide
- Sporanox (Itraconazole Capsules (Sporanox))-Lenvatinib
- Sporanox (Itraconazole Capsules (Sporanox))-Lenvatinib Mesylate